MedTrace Logo

Prediction of Primary Cardiovascular Events Using the Multimarker Approach

NCT05704569 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2023-03-15

No results posted yet for this study

Summary

The study of biochemical risk factors for cardiovascular diseases is important not only for analysis, but also for preventive measures, given that changes in the level of biomarkers can be detected before the first clinical manifestations of CVD. Accordingly, patients at high CV risk may have additional motivation to lead a healthy lifestyle. In addition, information on biochemical risk markers can be used to optimize the clinical management of patients.

Conditions

Interventions

DIAGNOSTIC_TEST

measurement of multiple biomarkers

All patients were tested for glucose and cholesterol levels. The capillary blood glucose level was measured by an electrochemical method using an Accu-Chek Active by AkkuChek blood glucose meter. The DM was considered to be verified when there were criteria which the World Health Organization (WHO) set in 2001: glucose concentration in whole blood is \>6.1 mmol/l, and glucose concentration is \>11.1 mmol/l in random measurement. Plasma for the study was obtained via the standard phlebotomy technique from ethylenediaminetetraacetic acid (EDTA) anticoagulants. Plasma was aliquoted into cryovials and got frozen quickly. The samples were stored in a low-temperature refrigerator (-70°C) until the study commencement (up to 3 months). All biomarkers were measured by magnetic bead-based multiplex immunofluorescence assay through the Xmap technology using the Milliplex map Human CVD Magnetic Bead Panel 1 (Millipore)

Sponsors & Collaborators

  • Karaganda Medical University

    lead OTHER

Principal Investigators

  • Lyudmila Turgunova, MD, PhD, ScD · Karaganda Medical University

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-06-01
Primary Completion
2020-03-01
Completion
2022-12-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05704569 on ClinicalTrials.gov